RxDoctor Payments DataLook up a doctor →

Dennis Marcus, MD

Ophthalmology · Augusta, GANPI 1851376776

Payments from drug & device makers

$9,239,956in general payments, 2019–2025

Across 846 payments — averaging $10,922 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$5.6M
  • Regeneron$1.3M
  • Ocular Therapeutix, Inc.$568K
  • Topcon Healthcare Solutions, Inc.$444K
  • Apellis Pharmaceuticals, Inc.$332K
  • Topcon Healthcare, Inc.$311K
  • plus $755K from 29 others
$23,568in research payments, 2019–2025

Across 18 payments — averaging $1309.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$19K
  • Regeneron$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,239,956 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$3,770,003
Medicare patients
1,066
Services billed
51,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →